AnaptysBio/$ANAB
1D1W1MYTD1Y5YMAX
Capital at risk
About AnaptysBio
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- Ticker
- $ANAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 104
- Headquarters
- San Diego, United States
- Website
- www.anaptysbio.com
AnaptysBio Metrics
BasicAdvanced
$1.5B
7.29
$7.00
0.41
-
Price and volume
Market cap
$1.5B
Beta
0.41
52-week high
$73.30
52-week low
$20.79
Average daily volume
474K
Financial strength
Current ratio
5.613
Quick ratio
5.538
Long term debt to equity
25.265
Total debt to equity
25.469
Interest coverage (TTM)
0.80%
Profitability
EBITDA (TTM)
65.714
Gross margin (TTM)
105.03%
Net profit margin (TTM)
246.96%
Operating margin (TTM)
61.93%
Effective tax rate (TTM)
3,562.75%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Valuation
Price to earnings (TTM)
7.287
Price to revenue (TTM)
13.931
Price to book
143.23
Price to tangible book (TTM)
143.23
Price to free cash flow (TTM)
-14.06
Free cash flow yield (TTM)
-7.11%
Free cash flow per share (TTM)
-3.627
Growth
What the Analysts think about AnaptysBio
Analyst ratings (Buy, Hold, Sell) for AnaptysBio stock.
Analyst projections of the future price of AnaptysBio stock.
Bulls say / Bears say
Jemperli is already producing strong momentum: GSK reported global sales of $644 million in the first half of 2026, up 34% year on year. Anaptys expects annualised royalties above $390 million as early as 2029 if GSK reaches its peak monotherapy sales guidance. (AnaptysBio)
Jemperli’s AZUR-1 trial met its primary objective in locally advanced dMMR/MSI-H rectal cancer, showing a meaningful clinical complete response rate sustained for 12 months. The FDA has set a February 2027 action date, creating a clear catalyst for a new indication and potentially higher royalties. (AnaptysBio, The Biotech Times)
Quimilza could add a second royalty stream without Anaptys funding development or commercialisation: Vanda pays a flat 10% royalty on future sales and bears those costs. Its FDA decision in generalised pustular psoriasis is scheduled for 12 December 2026. (StockAnalysis, AnaptysBio)
ANAB is now heavily dependent on partner execution, with Jemperli as its main royalty engine after the April 2026 separation of its research pipeline. That leaves investors exposed to one principal commercial asset rather than a diversified development portfolio. (AnaptysBio, AnaptysBio)
The Jemperli royalty stream is not yet fully available for shareholder returns: Anaptys expects Sagard’s remaining roughly $299 million of non-recourse royalty financing to be paid down only in the second half of 2027. Cash and investments also fell to $164.1 million by June 2026, limiting flexibility before that paydown. (AnaptysBio)
Two important sources of expected growth remain binary and unresolved: the FDA is due to decide on Quimilza in generalised pustular psoriasis in December 2026 and on Jemperli in rectal cancer in February 2027. A delay or rejection would weaken the case for a second royalty stream and for faster Jemperli growth. (AnaptysBio, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
AnaptysBio Financial Performance
Revenues and expenses
AnaptysBio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AnaptysBio
AllUSDEURGBP
Fund name | Fund size | $ANAB weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.11% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.11% |
iShares Healthcare Innovation£DRDR | £1B | 0.11% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.10% |
iShares Ageing Population€AGED | €822M | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.